Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 817

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 7
Chunk 817
---
,400,000 proceeds received in May and June 2025. As of March 31, 2025, our current
assets were $1,041,660 including $87,403 in cash and cash equivalents. In comparison, our current liabilities as of that date were
$1,362,369 including $1,014,259 of accounts payable and accrued expenses. Our working capital deficit as of March 31, 2024 was
$320,709.

The
Company has continued to realize losses from operations. However, as a result of our recent offerings, we believe we will have sufficient
cash to meet our anticipated operating costs and capital expenditure requirements for at least the next three months. We will need to
raise additional capital in the future to support our efforts to commercialize Spryng® and our ongoing operations. We expect to continue
to raise additional capital through the sale of our securities from time to time for the foreseeable future to fund our business expansion.
Our ability to obtain such additional capital will likely be subject to various factors, including our overall business performance and
market conditions. There can be no guarantee that the Company will be successful in its ability to raise additional capital to fund its
business plan.

29

Net
Cash Used in Operating Activities – We used $4,521,930 of net cash in operating activities in fiscal 2025. This cash used
in operating activities was primarily attributable to our net loss of $8,399,166, offset by stock based compensation of $1,107,520, and
an increase in accounts payable and accrued expenses of $1,155,038.

Net
Cash Used in Investing Activities – We used 1,063,436 of net cash in investing activities in fiscal 2025 due to the purchase
of the VetStem Licensing Agreement and the purchase of equipment.

Net
Cash Provided by Financing Activities – During fiscal 2025, we were provided with net cash of 5,725,652 from financing
activities consisting primarily of $1,818,000 from the proceeds of the sale of preferred stock, $2,050,100 from the proceeds of the sale
of common stock and warrants, and $1,565,000 from the proceeds of the issuance of convertible debentures.

Inventory

Inventories
are stated at cost, subject to the lower of cost or net realizable value. Cost includes materials, labor, and manufacturing overhead
related to the purchase and production of inventories. Net real